MYNZ Stock Risk & Deep Value Analysis
Mainz Biomed NV
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About MYNZ Stock
We analyzed Mainz Biomed NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MYNZ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is MYNZ Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for MYNZ?
- âš
Failure to secure additional funding, leading to operational constraints or bankruptcy
- âš
Negative FDA feedback, clinical trial delays, or outright rejection
- âš
Increased competition from existing or new non-invasive CRC tests
- âš
Further significant share dilution due to capital raises
Unlock MYNZ Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Mainz Biomed NV (MYNZ) Do?
Market Cap
$10.56M
Sector
Healthcare
Industry
Diagnostics & Research
Employees
19
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Visit Mainz Biomed NV WebsiteIs MYNZ Stock Undervalued?
Unlock the full AI analysis for MYNZ
Get the complete DVR score, risk analysis, and more
Does MYNZ Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
Highly fragile. While proprietary technology exists, it lacks robust market adoption, widespread regulatory approvals in key markets (US), and established brand loyalty to create a sustainable moat. Without significant capital and commercial execution, the IP alone will not create a durable competitive advantage against entrenched competitors.
Moat Erosion Risks
- •Failure to secure critical FDA approval for the US market
- •Stronger, more entrenched competition (e.g., Cologuard from Exact Sciences)
- •Lack of market access and reimbursement coverage in key regions
- •Inability to fund further development and commercialization efforts
MYNZ Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive MYNZ Stock Higher?
Near-Term (0-6 months)
- •Update on FDA regulatory pathway for ColoAlert (e.g., pre-submission meeting results)
- •Securing bridge financing or strategic investment (highly uncertain)
Medium-Term (6-18 months)
- •Positive interim clinical trial data for ColoAlert (e.g., for pivotal US study)
- •Partnership for European commercialization or expansion
Long-Term (18+ months)
- •Successful FDA approval and launch of ColoAlert in the US market
- •Securing significant payer reimbursement coverage for ColoAlert
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MYNZ?
- ✓
Major financing rounds or strategic partnerships that significantly de-risk the balance sheet
- ✓
Positive and concrete FDA communications or accelerated approval timelines for ColoAlert
- ✓
Significant and sustained insider buying (if it occurs) demonstrating strong conviction.
Bull Case Analysis
See what could go right with Premium
Compare MYNZ to Similar Stocks
See how Mainz Biomed NV stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MYNZ (Mainz Biomed NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
